Breast cancer (BC) has several distinct molecular subtypes, including estrogen receptor (ESR1) positive andtriple negative BC (TNBC). A significant proportion of ESR1-positive therapy sensitive-BCs (TS-BC) initiallyrespond to antiestrogens or aromatase inhibitors, but become therapy resistant-BCs (TR-BC) and progress toincurable metastases. Further, TNBC subtype has a more aggressive clinical course and lack targetedtherapies. Development of effective therapies for women with TR-BC and TNBCs represents the highest unmetneed.
A Collaboration of the San Antonio Bioscience and Medical Research Community
A first-of-its-kind initiative between public and private sector to catalog and highlight Bioscience research in the city of San Antonio and the surrounding areas.